乳糖酸阿奇霉素治疗100例急性感染性疾病疗效观察

Clinic observation of efficacy of azithromycin lactobionate for injection on treatment of 100 patients with acute infected Diseases.

目的 观察和评价乳糖酸阿奇霉素治疗急性感染性疾病的临床疗效、细菌学疗效和安全性。 方法 将确诊为呼吸系统感染的 12 0例患者和 40例皮肤软组织、性病患者共 160例 ,随机分为两组 ,乳糖酸阿奇霉素试验组10 0例 ,对照组乳糖酸红霉素 60例。病种为上呼吸道感染 3 0例 ,下呼吸道感染 90例 ,采用随机对照观察。皮肤软组织感染 2 0例 ,性病 2 0例开放观察。 结果 随机对照实验 ,乳糖酸阿奇霉素临床痊愈率 76.7% ,有效率 95 .0 % ,细菌清除率 94.8% ;红霉素组相应为 60 .0 % ,80 .0 % ,84.9% ,差异无显著性 (P >0 .0 5 )。开放试验乳糖酸阿奇霉素临床总痊愈率 83 .0 % ,有效率 94.0 % ,细菌清除率 93 .9%。乳糖酸阿奇霉素不良反应为 5 .6% ,红霉素为 2 3 .2 % ,差异有显著性 (P <0 .0 1)。 结论 注射用乳糖酸阿奇霉素临床疗效可靠 ,对治疗急性感染性疾病具有一定的临床价值 。

Objective To observe and evaluate the clinic efficacy, bacteriological effect and safety of Azithromycin Lactobionate injection for treatment of 100 patients with acute infected diseases. Methods Among 100 total 160 patients, we enrolled 100 patients in test group in which patients were treated by Azithromycin Lactobionate, and other 60 patients were in the control group in which patients were treated by Erythromycin Lactobionate. The acute infective disease included 30 patients of upper respiratory tract infection and 90 patients of lower respiratory tract infection, which were studied by randomized controlled trial; 20 patients of dermal parenchyma infection in addition to 20 patients of venereal infection were studied by open trial. Results In the randomized controlled trial, the clinic recovery rate of Azithromycin Lactobionate is 76.7%, the efficacy rate is 95.0% and the rate of bacterial elimination is 94.8%; compared to the above ,the corresponding rates of Erythromycin is 60.0%, 80.0% and 84.9%. There is no statistical significant difference between these two medicines(P>0.05). In the open trial, the clinic recory rate of Azithromycin Lactobionate is 83%, the efficacy rate is 94.0% and the rate of bacterial elimination is 93.9% . The rate of ADR of Azithromycin Lactobionate is 5.6%,and that of Erythromycin is 23.2%, which indicated a signinficant difference in statistics(P<0.01). Conclusion Azithromycin Lactobionate which has reliable clinic effect is worthy of application for the treatment of infective diseases.